Bora Lim

40PUBLICATIONS

289CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersMolecular targetsLiquid biopsies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (40)

Sort by Publication Date:

|May 13, 2026

Ecotypes of triple-negative breast cancer in response to chemotherapy.

|Oct 21, 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease).

Bora Lim, Angela Marx, Megumi Kai

|Aug 27, 2025

NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitors.

Ze-Yi Zheng, Anran Chen, Eric J Jaehnig

|Jun 13, 2025

Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.

Andrew J Kinloch, Faiyaz Rahman, Bahriye Karakas

|May 13, 2025

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers.

Mohd Mughees, Moises Tacam, Alex W Tan

|Jan 21, 2025

Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.

Rahat Alam, Anna Reva, David G Edwards

Pageof 7

Frequent Collaborators

12 joint publications

Naoto Ueno

Debu Tripathy

Jason White

Jonathan T Lei

Meenakshi Anurag

Nicholas Navin

Matthew J Ellis

Jennifer K Litton

Gabriel N Hortobagyi

Roland L Bassett

Frequent Collaborators

12 joint publications

Naoto Ueno

9 joint publications

Debu Tripathy

5 joint publications

Jason White

4 joint publications

Jonathan T Lei